105
Participants
Start Date
September 27, 2022
Primary Completion Date
March 27, 2028
Study Completion Date
February 27, 2030
Atezolizumab
1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
Bevacizumab
15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
UCPVax
UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
RECRUITING
CHU de Besançon, Besançon
RECRUITING
CH William Morey, Chalon-sur-Saône
RECRUITING
Hôpital Henri Mondor, Créteil
RECRUITING
Centre Georges François Leclerc, Dijon
RECRUITING
Hôpital Nord Franche-Comté, Montbéliard
RECRUITING
CHU de Montpellier, Montpellier
RECRUITING
CH de Mulhouse, Mulhouse
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Nantes
NOT_YET_RECRUITING
Centre Hospitalier Paris St Joseph, Paris
RECRUITING
Groupe Hospitalier Paris Salpetrière, Paris
RECRUITING
Hôpital BEAUJON, Paris
RECRUITING
Institut Mutualiste Montsouris, Paris
NOT_YET_RECRUITING
CHU de Poitiers, Poitiers
RECRUITING
Hôpital Paul Brousse, Villejuif
Collaborators (1)
GERCOR - Multidisciplinary Oncology Cooperative Group
OTHER
PRODIGE
UNKNOWN
Centre Hospitalier Universitaire de Besancon
OTHER